Kyverna Therapeutics, Inc. - 10-Q Filing
Kyverna Therapeutics filed its quarterly report for March 31, 2026, disclosing financial results and operational updates. The company reported a net loss of $58 million compared to a net loss of $49 million in the same period last year due to increased research and development expenses related to its Miv-Cel program and other initiatives. Kyverna also provided an update on its loan agreements, including Tranche One through Three under its Term Loan Facility.
Tickers: $KYTX